|Tonix Pharmaceuticals Holding Corp.|
509 Madison Avenue
United States - Map
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. The company's lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase II clinical stage for the treatment of post-traumatic stress disorder. It also engages in developing TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.
|Dr. Seth Lederman M.D.,
Co-Founder, Chairman, and Chief Exec. Officer
|Dr. Donald W. Landry M.D., Ph.D.,
Co-Founder and Director
|Mrs. Jessica Edgar Morris ,
Exec. VP of Operations
|Dr. Bruce L. Daugherty Ph.D., M.B.A.,
Chief Scientific Officer, Controller and Sec.
|Dr. Gregory M. Sullivan M.D.,
Chief Medical Officer
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|